Efficacy and Safety of Two Resilient Hyaluronic Acid Fillers in the Treatment of Moderate-to-Severe Nasolabial Folds
- Author: Gary Monheit, M.D.
Journal of the American Academy of Dermatology
Plastic and Reconstructive Surgery
Journal of Cosmetic Dermatology
Disclaimer: DaxibotulinumtoxinA for Injection is currently an investigational product and not approved by FDA. Anticipated approval in 2020.
More than 73.5% subjects in Sakura 1 and 2 achieved a two-grade improvement in glabellar lines as assessed by with the patient and the investigator at week 4 after treatment1
DaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. Anticipated approval in 2020
* DaxibotulinumtoxinA for Injection was formerly known as RT002.